Bould Opportunities plc’s £21 Million Acquisition Of Cizzle Biotechnology Limited

Goodman Derrick advised Bould Opportunities plc on the deal.

Bould Opportunities plc acquired Cizzle Biotechnology Limited, Bould’s associated £2.2m fundraising and the admission of the enlarged group to trading on the Main Market of the London Stock Exchange.  The proposals are conditional upon the approval of Bould’s shareholders at a forthcoming General Meeting.

Cizzle – a biotech spinout of the University of York – was founded in 2006 and has developed a patent protected technology for the early detection of lung cancer through the development of a blood test for the CIZ1B biomarker.

Bould have conditionally raised £2.2million by way of a Placing in order to provide working capital for the Enlarged Group’s strategy.

The Goodman Derrick corporate team, led by Dominic Prentis (Picture) and Richard Pull, have provided insightful and practical legal guidance throughout. The team included Alexandra Bonner, Partner, Employment, Remy Ormesher, Associate, Employment.

Keith Spedding, Jennie Davis and Gweni Rees-Evans of Shakespeare Martineau acted for Cizzle.  Also advising on the transaction were: IFC Advisory Limited (Financial PR & IR), Allenby Capital Limited (Finance Adviser), Novum Securities Limited (Broker). 

Involved fees earner: Alexandra Bonner – Goodman Derrick; Remy Ormesher – Goodman Derrick; Dominic Prentis – Goodman Derrick; Richard Pull – Goodman Derrick;

Law Firms: Goodman Derrick;

Clients: Bould Opportunities plc ;

Author: Federica Tiefenthaler